Abstract:ImportanceOf approximately 9 million patients with cancer in China in 2020, more than half were diagnosed with late-stage cancers. Recent regulatory reforms in China have focused on improving the availability of new cancer drugs. However, evidence on the clinical benefits of new cancer therapies authorized in China is not available.ObjectiveTo characterize the clinical benefits of cancer drugs approved in China, as defined by the availability and magnitude of statistically significant overall survival (OS) results.Design, Setting, and ParticipantsThis mixed-methods study comprising a systematic review and cross-sectional analysis identified antineoplastic agents approved in China between January 1, 2005, and December 31, 2020, using publicly available data and regulatory review documents issued by the National Medical Products Administration. The literature published up to June 30, 2021, was reviewed to collect results on end points used in pivotal trials supporting cancer drug approvals.Main Outcomes and MeasuresThe primary outcome measure was a documented statistically significant positive OS difference between a new cancer therapy and a comparator treatment. Secondary outcome measures were the magnitude of OS benefit and other primary efficacy measures in pivotal trials.ResultsBetween 2005 and 2020, 78 cancer drugs corresponding to 141 indications were authorized in China, including 20 drugs (25.6%) (for 30 indications) approved in China only. Of all indications, 26 (18.4%) were evaluated in single-arm or dose-optimization trials, most of which were authorized after 2017. By June 30, 2021, 34 drug indications (24.1%) had a documented lack of OS gain. For 68 indications (48.2%) that had documented evidence of OS benefit, the median magnitude of OS improvement was 4.1 (range, 1.0-35.0) months. After a median follow-up of 1.9 (range, 1.0-11.1) years from approval, OS data for 13 indications (9.2%) were either not reported or were still not mature. Fewer than one-third of cancer drug indications approved in China only had documented evidence of OS benefits (9 of 30 [30.0%]), whereas more than one-half of the cancer drug indications also available in the US or Europe had OS benefits (59 of 111 [53.1%]).Conclusions and RelevanceIn this study, almost half of cancer drug indications approved in China had demonstrated OS gain. With the increase of cancer drug approvals based on single-arm trials or immature survival data in recent years, these findings highlight the need to routinely monitor the clinical benefits of new cancer therapies in China.

Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China

Access to innovative anticancer medicines in China: a national survey on availability, price and affordability

Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study

Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis

Access to anticancer medicines in public hospitals of Northwestern China

Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective

Differences in reimbursement listing of anticancer therapies in China: an observational study

Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis

How Government Insurance Coverage Changed the Utilization and Affordability of Expensive Targeted Anti-Cancer Medicines in China: an Interrupted Time-Series Study

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study

Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States

The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data

New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study

The price and affordability of essential medicines, progress and regional distribution in China: a systematic review

Traditional Chinese Patent Medicines for Cancer Treatment in China: a Nationwide Medical Insurance Data Analysis.

Overall Survival Benefits of Cancer Drugs Approved in China from 2005 to 2020

Using Health Technology Assessment to Inform Insurance Reimbursement of High Technology Medicines in China: an Example of Cancer Immunotherapy

Antineoplastic Prescription among Patients with Colorectal Cancer in Eight Major Cities of China, 2015–2019: an Observational Retrospective Database Analysis

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis

Challenges in Anticancer Drug R&D in China